Jeffrey Apter
Psychiatry · Princeton, NJNPI 1568509495
Payments from drug & device makers
Across 555 payments — averaging $3057.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$855K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$238K
- Sage Therapeutics, LLC$195K
- Janssen Research & Development, LLC$170K
- Eli Lilly$84K
- Supernus Pharmaceuticals, Inc.$78K
- plus $78K from 30 others
Across 20 payments — averaging $5729.25 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Arbor Pharmaceuticals, Inc.$112K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$2K
- Eli Lilly$677
- AbbVie$127
What the payments were for
- Speaking & faculty fees$3,42027%
- Travel & lodging$2,17417%
- Food & beverage$6,90155%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Jornay PM 20mg capsules (Bottle of 100)$4,879
- LYBALVI$405
- REXULTI$346
- Dyanavel XR$271
- CAPLYTA$125
- VRAYLAR$110
How this compares
$1,696,635 in reported general payments places this provider in the 95th percentile of 1,119 psychiatry providers in New Jersey.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 11 | $15,160 |
| RexultiBrexpiprazole | 18 | $13,481 |
| Clonazepam | 23 | $378 |
| Mirtazapine | 14 | $290 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar | $854,748 | $15,16011 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $588 | $13,48118 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,119 psychiatry providers in New Jersey.
Other psychiatry in Princeton
- Sanjay VarmaPrinceton$479K
- Leon RosenbergCherry Hill$6.4M
- Steven GlassClementon$3.9M
- Judith JosephPaterson$3.8M
- Roberta BallCherry Hill$741K
- Marc CantillonLivingston$524K
- Manuel SanchezNewark$474K
- Robert BransfieldRed Bank$415K
- Erika ConcepcionLong Branch$354K
- Tapan ParikhCamden$275K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.